Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

The Tumor Microenvironment in Colorectal Cancer Therapy.

Pedrosa L, Esposito F, Thomson TM, Maurel J.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1172. doi: 10.3390/cancers11081172. Review.

2.

Metabolic Plasticity and Epithelial-Mesenchymal Transition.

Thomson TM, Balcells C, Cascante M.

J Clin Med. 2019 Jul 3;8(7). pii: E967. doi: 10.3390/jcm8070967. Review.

3.

Metabolic Alterations in Cardiopulmonary Vascular Dysfunction.

Smolders VF, Zodda E, Quax PHA, Carini M, Barberà JA, Thomson TM, Tura-Ceide O, Cascante M.

Front Mol Biosci. 2019 Jan 22;5:120. doi: 10.3389/fmolb.2018.00120. eCollection 2018. Review.

4.

Epithelial plasticity in cancer: beyond metastasis.

Thomson TM, Fernández PL.

Aging (Albany NY). 2018 Jan 22;10(1):3-4. doi: 10.18632/aging.101367. No abstract available.

5.

Model-driven discovery of long-chain fatty acid metabolic reprogramming in heterogeneous prostate cancer cells.

Marín de Mas I, Aguilar E, Zodda E, Balcells C, Marin S, Dallmann G, Thomson TM, Papp B, Cascante M.

PLoS Comput Biol. 2018 Jan 2;14(1):e1005914. doi: 10.1371/journal.pcbi.1005914. eCollection 2018 Jan.

6.

MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells.

Sánchez-Cid L, Pons M, Lozano JJ, Rubio N, Guerra-Rebollo M, Soriano A, Paris-Coderch L, Segura MF, Fueyo R, Arguimbau J, Zodda E, Bermudo R, Alonso I, Caparrós X, Cascante M, Rafii A, Kang Y, Martínez-Balbás M, Weiss SJ, Blanco J, Muñoz M, Fernández PL, Thomson TM.

Oncotarget. 2017 Sep 7;8(48):83384-83406. doi: 10.18632/oncotarget.20698. eCollection 2017 Oct 13.

7.

De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition.

Tarrado-Castellarnau M, de Atauri P, Tarragó-Celada J, Perarnau J, Yuneva M, Thomson TM, Cascante M.

Mol Syst Biol. 2017 Oct 4;13(10):940. doi: 10.15252/msb.20167321.

8.

Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.

Campbell CT, Haladyna JN, Drubin DA, Thomson TM, Maria MJ, Yamauchi T, Waters NJ, Olhava EJ, Pollock RM, Smith JJ, Copeland RA, Blakemore SJ, Bernt KM, Daigle SR.

Mol Cancer Ther. 2017 Aug;16(8):1669-1679. doi: 10.1158/1535-7163.MCT-16-0693. Epub 2017 Apr 20.

9.

A key role for transketolase-like 1 in tumor metabolic reprogramming.

Diaz-Moralli S, Aguilar E, Marin S, Coy JF, Dewerchin M, Antoniewicz MR, Meca-Cortés O, Notebaert L, Ghesquière B, Eelen G, Thomson TM, Carmeliet P, Cascante M.

Oncotarget. 2016 Aug 9;7(32):51875-51897. doi: 10.18632/oncotarget.10429.

10.

Metabolic Reprogramming and Dependencies Associated with Epithelial Cancer Stem Cells Independent of the Epithelial-Mesenchymal Transition Program.

Aguilar E, Marin de Mas I, Zodda E, Marin S, Morrish F, Selivanov V, Meca-Cortés Ó, Delowar H, Pons M, Izquierdo I, Celià-Terrassa T, de Atauri P, Centelles JJ, Hockenbery D, Thomson TM, Cascante M.

Stem Cells. 2016 May;34(5):1163-76. doi: 10.1002/stem.2286. Epub 2016 Feb 2.

11.

Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis.

Thomson TM, Lescarbeau RM, Drubin DA, Laifenfeld D, de Graaf D, Fryburg DA, Littman B, Deehan R, Van Hooser A.

BMC Med Genomics. 2015 Jun 3;8:26. doi: 10.1186/s12920-015-0100-6.

12.

SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations.

Mateo F, Meca-Cortés O, Celià-Terrassa T, Fernández Y, Abasolo I, Sánchez-Cid L, Bermudo R, Sagasta A, Rodríguez-Carunchio L, Pons M, Cánovas V, Marín-Aguilera M, Mengual L, Alcaraz A, Schwartz S Jr, Mellado B, Aguilera KY, Brekken R, Fernández PL, Paciucci R, Thomson TM.

Mol Cancer. 2014 Oct 21;13:237. doi: 10.1186/1476-4598-13-237.

13.

An algorithm for score aggregation over causal biological networks based on random walk sampling.

Vasilyev DM, Thomson TM, Frushour BP, Martin F, Sewer A.

BMC Res Notes. 2014 Aug 11;7:516. doi: 10.1186/1756-0500-7-516.

14.

Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression.

Alaña L, Sesé M, Cánovas V, Punyal Y, Fernández Y, Abasolo I, de Torres I, Ruiz C, Espinosa L, Bigas A, Y Cajal SR, Fernández PL, Serras F, Corominas M, Thomson TM, Paciucci R.

Mol Cancer. 2014 Mar 31;13:74. doi: 10.1186/1476-4598-13-74.

15.

Infrequent loss of luminal differentiation in ductal breast cancer metastasis.

Calvo J, Sánchez-Cid L, Muñoz M, Lozano JJ, Thomson TM, Fernández PL.

PLoS One. 2013 Oct 21;8(10):e78097. doi: 10.1371/journal.pone.0078097. eCollection 2013.

16.

Quantitative assessment of biological impact using transcriptomic data and mechanistic network models.

Thomson TM, Sewer A, Martin F, Belcastro V, Frushour BP, Gebel S, Park J, Schlage WK, Talikka M, Vasilyev DM, Westra JW, Hoeng J, Peitsch MC.

Toxicol Appl Pharmacol. 2013 Nov 1;272(3):863-78. doi: 10.1016/j.taap.2013.07.007. Epub 2013 Aug 8.

17.

Stem cells in prostate cancer.

Mateo F, Fernandez PL, Thomson TM.

Arch Esp Urol. 2013 Jun;66(5):475-86. Review.

PMID:
23793765
18.

Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1.

Marqués N, Sesé M, Cánovas V, Valente F, Bermudo R, de Torres I, Fernández Y, Abasolo I, Fernández PL, Contreras H, Castellón E, Celià-Terrassa T, Méndez R, Ramón Y Cajal S, Thomson TM, Paciucci R.

Oncogene. 2014 Feb 27;33(9):1124-34. doi: 10.1038/onc.2013.51. Epub 2013 Mar 4.

PMID:
23455324
19.

Acid ceramidase as a therapeutic target in metastatic prostate cancer.

Camacho L, Meca-Cortés O, Abad JL, García S, Rubio N, Díaz A, Celià-Terrassa T, Cingolani F, Bermudo R, Fernández PL, Blanco J, Delgado A, Casas J, Fabriàs G, Thomson TM.

J Lipid Res. 2013 May;54(5):1207-20. doi: 10.1194/jlr.M032375. Epub 2013 Feb 19.

20.

Identification of RNF8 as a ubiquitin ligase involved in targeting the p12 subunit of DNA polymerase δ for degradation in response to DNA damage.

Zhang S, Zhou Y, Sarkeshik A, Yates JR 3rd, Thomson TM, Zhang Z, Lee EY, Lee MY.

J Biol Chem. 2013 Feb 1;288(5):2941-50. doi: 10.1074/jbc.M112.423392. Epub 2012 Dec 11. Erratum in: J Biol Chem. 2014 Jan 17;289(3):1212.

21.

Nucleolar exit of RNF8 and BRCA1 in response to DNA damage.

Guerra-Rebollo M, Mateo F, Franke K, Huen MS, Lopitz-Otsoa F, Rodríguez MS, Plans V, Thomson TM.

Exp Cell Res. 2012 Nov 1;318(18):2365-76. doi: 10.1016/j.yexcr.2012.07.003. Epub 2012 Jul 16.

PMID:
22814251
22.

Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks.

Martin F, Thomson TM, Sewer A, Drubin DA, Mathis C, Weisensee D, Pratt D, Hoeng J, Peitsch MC.

BMC Syst Biol. 2012 May 31;6:54. doi: 10.1186/1752-0509-6-54.

23.

Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells.

Celià-Terrassa T, Meca-Cortés O, Mateo F, Martínez de Paz A, Rubio N, Arnal-Estapé A, Ell BJ, Bermudo R, Díaz A, Guerra-Rebollo M, Lozano JJ, Estarás C, Ulloa C, Álvarez-Simón D, Milà J, Vilella R, Paciucci R, Martínez-Balbás M, de Herreros AG, Gomis RR, Kang Y, Blanco J, Fernández PL, Thomson TM.

J Clin Invest. 2012 May;122(5):1849-68. doi: 10.1172/JCI59218. Epub 2012 Apr 16.

24.

A network-based approach to quantifying the impact of biologically active substances.

Hoeng J, Deehan R, Pratt D, Martin F, Sewer A, Thomson TM, Drubin DA, Waters CA, de Graaf D, Peitsch MC.

Drug Discov Today. 2012 May;17(9-10):413-8. doi: 10.1016/j.drudis.2011.11.008. Epub 2011 Dec 2. No abstract available.

PMID:
22155224
25.

Scaffold number in yeast signaling system sets tradeoff between system output and dynamic range.

Thomson TM, Benjamin KR, Bush A, Love T, Pincus D, Resnekov O, Yu RC, Gordon A, Colman-Lerner A, Endy D, Brent R.

Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20265-70. doi: 10.1073/pnas.1004042108. Epub 2011 Nov 23.

26.

Highly sensitive molecular diagnosis of prostate cancer using surplus material washed off from biopsy needles.

Bermudo R, Abia D, Mozos A, García-Cruz E, Alcaraz A, Ortiz AR, Thomson TM, Fernández PL.

Br J Cancer. 2011 Nov 8;105(10):1600-7. doi: 10.1038/bjc.2011.435. Epub 2011 Oct 18.

27.

Differential regulation of RNF8-mediated Lys48- and Lys63-based poly-ubiquitylation.

Lok GT, Sy SM, Dong SS, Ching YP, Tsao SW, Thomson TM, Huen MS.

Nucleic Acids Res. 2012 Jan;40(1):196-205. doi: 10.1093/nar/gkr655. Epub 2011 Sep 12.

28.

Discovery of genomic alterations through coregulation analysis of closely linked genes: a frequent gain in 17q25.3 in prostate cancer.

Bermudo R, Abia D, Benitez D, Carrió A, Vilella R, Ortiz AR, Thomson TM, Fernández PL.

Ann N Y Acad Sci. 2010 Oct;1210:17-24. doi: 10.1111/j.1749-6632.2010.05780.x.

PMID:
20973795
29.

Protein-protein interaction antagonists as novel inhibitors of non-canonical polyubiquitylation.

Scheper J, Guerra-Rebollo M, Sanclimens G, Moure A, Masip I, González-Ruiz D, Rubio N, Crosas B, Meca-Cortés O, Loukili N, Plans V, Morreale A, Blanco J, Ortiz AR, Messeguer A, Thomson TM.

PLoS One. 2010 Jun 30;5(6):e11403. doi: 10.1371/journal.pone.0011403.

30.

Monoubiquitination of RPN10 regulates substrate recruitment to the proteasome.

Isasa M, Katz EJ, Kim W, Yugo V, González S, Kirkpatrick DS, Thomson TM, Finley D, Gygi SP, Crosas B.

Mol Cell. 2010 Jun 11;38(5):733-45. doi: 10.1016/j.molcel.2010.05.001.

31.

Regulation of aurora B kinase by the lipid raft protein flotillin-1.

Gómez V, Sesé M, Santamaría A, Martínez JD, Castellanos E, Soler M, Thomson TM, Paciucci R.

J Biol Chem. 2010 Jul 2;285(27):20683-90. doi: 10.1074/jbc.M110.130591. Epub 2010 Apr 29.

32.

Ubiquitin and SUMO signalling in DNA repair.

Thomson TM, Guerra-Rebollo M.

Biochem Soc Trans. 2010 Feb;38(Pt 1):116-31. doi: 10.1042/BST0380116. Review.

PMID:
20074046
33.

Searching for the boundaries: unlimited expansion of ubiquitin and ubiquitin-like signals in multiple cellular functions.

Crosas B, Farràs R, Marfany G, Rodríguez MS, Thomson TM.

Biochem Soc Trans. 2010 Feb;38(Pt 1):1-5. doi: 10.1042/BST0380001.

PMID:
20074026
34.

HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells.

Soler M, Mancini F, Meca-Cortés O, Sánchez-Cid L, Rubio N, López-Fernández S, Lozano JJ, Blanco J, Fernández PL, Thomson TM.

Int J Cancer. 2009 Dec 1;125(11):2565-75. doi: 10.1002/ijc.24651.

35.

The Alpha Project: a model system for systems biology research.

Yu RC, Resnekov O, Abola AP, Andrews SS, Benjamin KR, Bruck J, Burbulis IE, Colman-Lerner A, Endy D, Gordon A, Holl M, Lok L, Pesce CG, Serra E, Smith RD, Thomson TM, Tsong AE, Brent R.

IET Syst Biol. 2008 Sep;2(5):222-33. doi: 10.1049/iet-syb:20080127. Review.

36.

Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer.

Bermudo R, Abia D, Ferrer B, Nayach I, Benguria A, Zaballos A, del Rey J, Miró R, Campo E, Martínez-A C, Ortiz AR, Fernández PL, Thomson TM.

BMC Cancer. 2008 Oct 30;8:315. doi: 10.1186/1471-2407-8-315.

37.

Analysis of electrostatic contributions to the selectivity of interactions between RING-finger domains and ubiquitin-conjugating enzymes.

Scheper J, Oliva B, Villà-Freixa J, Thomson TM.

Proteins. 2009 Jan;74(1):92-103. doi: 10.1002/prot.22120.

PMID:
18615712
38.

Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase.

Kolas NK, Chapman JR, Nakada S, Ylanko J, Chahwan R, Sweeney FD, Panier S, Mendez M, Wildenhain J, Thomson TM, Pelletier L, Jackson SP, Durocher D.

Science. 2007 Dec 7;318(5856):1637-40. Epub 2007 Nov 15.

39.

Regulation of mitotic exit by the RNF8 ubiquitin ligase.

Plans V, Guerra-Rebollo M, Thomson TM.

Oncogene. 2008 Feb 28;27(10):1355-65. Epub 2007 Sep 3.

PMID:
17724460
40.

Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells.

Hurtado M, Lozano JJ, Castellanos E, López-Fernández LA, Harshman K, Martínez-A C, Ortiz AR, Thomson TM, Paciucci R.

Gut. 2007 Sep;56(9):1266-74. Epub 2007 Apr 23.

41.

Tandem chimerism as a means to increase protein complexity in the human genome.

Parra G, Reymond A, Dabbouseh N, Dermitzakis ET, Castelo R, Thomson TM, Antonarakis SE, Guigó R.

Genome Res. 2006 Jan;16(1):37-44. Epub 2005 Dec 12.

42.

The RING finger protein RNF8 recruits UBC13 for lysine 63-based self polyubiquitylation.

Plans V, Scheper J, Soler M, Loukili N, Okano Y, Thomson TM.

J Cell Biochem. 2006 Feb 15;97(3):572-82.

PMID:
16215985
43.
44.

PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts.

Santamaría A, Castellanos E, Gómez V, Benedit P, Renau-Piqueras J, Morote J, Reventós J, Thomson TM, Paciucci R.

Mol Cell Biol. 2005 Mar;25(5):1900-11.

45.

A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma.

Planagumà J, Díaz-Fuertes M, Gil-Moreno A, Abal M, Monge M, García A, Baró T, Thomson TM, Xercavins J, Alameda F, Reventós J.

Cancer Res. 2004 Dec 15;64(24):8846-53.

47.

PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle.

Santamaría A, Fernández PL, Farré X, Benedit P, Reventós J, Morote J, Paciucci R, Thomson TM.

Am J Pathol. 2003 Mar;162(3):897-905.

48.

Expression and regulation of the transcriptional repressor ZNF43 in Ewing sarcoma cells.

González-Lamuño D, Loukili N, García-Fuentes M, Thomson TM.

Pediatr Pathol Mol Med. 2002 Nov-Dec;21(6):531-40.

PMID:
12537770
49.

Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells.

Díaz VM, Planaguma J, Thomson TM, Reventós J, Paciucci R.

Gastroenterology. 2002 Mar;122(3):806-19. Erratum in: Gastroenterology 2002 Jul;123(1):397. Gastroenterology. 2003 May 12;124(5):1568.

PMID:
11875015
50.

PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks.

Benedit P, Paciucci R, Thomson TM, Valeri M, Nadal M, Càceres C, de Torres I, Estivill X, Lozano JJ, Morote J, Reventós J.

Oncogene. 2001 Mar 22;20(12):1455-64.

Supplemental Content

Loading ...
Support Center